Will priming intravenous administration sets with monoclonal antibodies reduce chair time in the outpatient setting? (The priming practice study)

Not Applicable

Recruiting

• Conditions: Melanoma; Cancer - Myeloma; Myeloma; Lekaemia; Lymphoma; Lung Cancer; Cancer - Leukaemia - Chronic leukaemia; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma; Cancer - Lung - Non small cell; Cancer - Malignant melanoma

• Registration Number: ACTRN12621000933853
• Lead Sponsor: .Royal Brisbane and Women's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-16
• Last Update Posted: 26 July 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

1. Patients attending the Oncology Day Therapy Unit or Oncology Procedure Unit
2.18 years or older
3.Are being treated with the single agent monoclonal antibodies: Obinutuzumab, Daratumumab, Nivolumab, Pembrolizumab.
4.Any cycle of a patient’s treatment regime (e.g, 1st, 2nd, 3rd dose)

Exclusion Criteria

The exclusion criteria:
1.Under 18 years of age
2.Patients receiving treatment with a monoclonal antibody as an inpatient or at North Lakes
3.Patients receiving any other monoclonal antibodies that do not meet the criteria of inclusion drugs, chemotherapy, supportive therapies or treatment as part of a pharmaceutical clinical trial
4.No funding to approach patients who require a translator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chair time, this will be collected through a data collection form. This form has been designed specifically for this study. [Chair time will be measured by duration of infusion. (From the time the infusion commenced until the time the infusion completed)]